Release Date: December 10, 2022
Expiration Date: February 1, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is intended for medical oncologists, hematologist/oncologists, hematologists, primary care physicians, hematopathologists, and other healthcare professionals interested in understanding the current treatment guidelines and diagnostic strategies for patients who present with hematologic symptoms of unknown origin.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine key processes and criteria for differential diagnosis of rare hematologic disorders
- Explain the pathophysiology of rare blood disorders and its relationship to diagnosis confirmation, and treatment decisions
- Integrate emerging data and updated guidelines into personalized treatment plans for patients with rare hematologic disorders
- Apply strategies to timely monitor and mitigate disease- and treatment-related adverse events in patients with rare blood disorders
Pramod K. Mistry, MD, PhD, FRCP, FAASLD
Professor of Medicine and Pediatrics
Professor of Cellular and Molecular Physiology
Yale School of Medicine
New Haven, CT
Disclosures: Grant/Research Support: Sanofi; Other: Research grant and travel support
Pavan K. Bendapudi, MD
Assistant Professor of Medicine
Harvard Medical School
Division of Hematology and Blood Transfusion Service
Massachusetts General Hospital
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center
Boston, MA
Disclosures: Consultant: Alexion Pharmaceuticals, Inc., Millennium Pharmaceuticals/ Takeda, SQZ Biotechnologies, Verve Therapeutics
Nichola Cooper, MD, MA, MBBS, FRCP
Senior Lecturer and Honorary Consultant Hematologist
Hammersmith Hospital
Imperial College London
London, UK
Disclosures: Grant/Research Support: Novartis, Rigel Pharmaceuticals, Inc.; Consultant: Amgen, argenyx, Grifols, Novartis, Rigel Pharmaceuticals, Inc., Sanofi, Sobi, UCB; Other: Reader in Immune Hematology at Imperial College
Eli Muchtar, MD
Associate Professor of Medicine
Mayo Clinic College of Medicine and Science
Rochester, MN
Disclosures: Consultant: Protego Biopharma, Inc; Speakers’ Bureau: Janssen
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
